Katarina Rak’s Post

FeNO can help identify asthma patients who are more likely to respond to biologics, allowing for a personalized approach to treatment. Available at the point-of-care, FeNO testing is quick and can even be performed by patients with severely reduced lung function. Discover the gold standard in FeNO testing, NIOX VERO®, today: https://lnkd.in/gGtSb6AR

Thoughts on this? >> Sage reports Phase 2 failure in Huntington's disease, ends drug's development >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #productmarketing #pharma #biotech

Discover Resmetirom and its role in treating MASH with Robin Soto, NP! This new medication review explains the first and only FDA-approved drug for managing MASH in adults with mild to moderate fibrosis. Explore an in-depth look at how Resmetirom functions as an innovative treatment option at https://loom.ly/8tBxawA

FeNO can help identify asthma patients who are more likely to respond to biologics, allowing for a personalized approach to treatment. Available at the point-of-care, FeNO testing is quick and can even be performed by patients with severely reduced lung function. Discover the gold standard in FeNO testing, NIOX VERO®, today: https://lnkd.in/gGtSb6AR

FeNO can help identify asthma patients who are more likely to respond to biologics, allowing for a personalized approach to treatment. Available at the point-of-care, FeNO testing is quick and can even be performed by patients with severely reduced lung function. Discover the gold standard in FeNO testing, NIOX VERO®, today: https://lnkd.in/gGtSb6AR

📈 Continuous Glucose Monitoring Market on the Rise The American Diabetes Association reported in November 2023 that about 1.2 million US citizens are diagnosed with diabetes every year. This alarming trend is driving demand for advanced monitoring technologies, particularly in the continuous glucose monitoring (CGM) market. A recent milestone: In March 2024, Dexcom received FDA clearance for Stelo, a non-prescription CGM designed for Type 2 diabetes patients who don’t use insulin. 🔗 Discover more in our detailed report: https://shorturl.at/Dj1J8 Major Players: Dexcom | Abbott | Senseonics, Incorporated | Medtronic | Roche #DiabetesAwareness #HealthcareInnovation #ContinuousGlucoseMonitoring #WearableTech #mordorintelligence

Notes to Myself: After spending more than a decade in Diabetes TA, my concern is that 20% of the Diabetics get into uncontrolled diabetes. They become " Stubborn Diabetics" and end up developing Diabetic complication. Some lose their limbs, some their kidneys and some end up with CVD. How can we " Pharma professionals ' help save the patients from becoming " Stubborn Diabetics" Inviting discussion on this topic!

My lecture titled ( Holistic approach in type 2 diabetes management ) as a CME activity , in the Launch event for a new oral antihyperglycemic drug

📣 Big news alert! 📣 The FDA has accepted our New Drug Application (NDA) and has set a PDUFA date of June 28, 2025 for making an approval decision on our lead asset, Oxylanthanum Carbonate (OLC). If approved, OLC will provide patients with chronic kidney disease on dialysis a hyperphosphatemia treatment with a potential best-in-class profile that could offer meaningful patient adherence benefits due to lower pill burden in terms of number and size of pills per dose that are swallowed instead of chewed. We’re thrilled to be one step closer to potentially delivering a much needed next-gen solution to many patients. Learn more here: https://lnkd.in/gyrwhbTh #KidneyDisease

Thoughts on this? >> Sage reports Phase 2 failure in Huntington's disease, ends drug's development >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #biotech #pharmaceutical